相关实验视频
Updated: Jan 6, 2026
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
11.4K
在患有晚期上皮质卵巢癌的患者中,试验招生和生存差异
Caitlin Ruth Johnson1, Alex A Francoeur2, Amandeep Grewal1
1Sutter Health, Walnut Creek, California.
JAMA network open
|October 22, 2025
概括
黑人患有上皮卵巢癌的患者的整体存活率较低,但在临床试验中类似的无进展存活率. 改善试验多样性对于公平的癌症护理和生存结果至关重要.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 健康 公平 卫生 公平
背景情况:
- 皮质卵巢癌 (EOC) 的种族差异可能导致生存不平等.
- 妇科瘤学组 (GOG) 的随机临床试验 (RCT) 对于推进EOC治疗至关重要.
- 在EOCRCT中评估种族入学率和结果对于理解和解决生存差距至关重要.
研究的目的:
- 在GOG RCT中评估EOC患者的种族代表性和结果.
- 为了确定亚洲,黑人和白人EOC患者的潜在生存差异.
- 为改善癌症临床试验多样性和公平性的策略提供信息.
主要方法:
- 使用GOGRCT (GOG-111,GOG-114,GOG-158,GOG-172) 的辅助数据进行的回顾性队列研究.
- 分析包括1903名患有III或IV期EOC的患者,按种族 (亚洲人,黑人,白人) 分类.
- 总生存 (OS) 和无进展生存 (PFS) 用多变量Cox比例风险建模来评估.
主要成果:
- 与白人患者 (91.80%) 相比,黑人患者 (6.36%) 和亚洲患者 (1.84%) 的比例较低.
- 与白人 (48.4个月) 和亚洲人 (50.9个月) 患者相比,黑人患者的生存期 (36.8个月) 显着较低 (P=.03).
- 无进展生存期 (PFS) 和疾病进展风险在各种族群体中统计上相似.
结论:
- 在这项研究中,患有EOC的黑人患者的整体存活率较低,但与白人和亚洲患者的无进展存活率相似.
- 黑人和亚洲患者在EOCRCT中的代表性不足凸显了改善试验多样性的需要.
- 加强临床试验的公平招生对于实现所有种族群体之间可比的癌症治疗结果和存活率至关重要.
相关概念视频
01:21Cancer Survival Analysis
624
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
624
01:20Comparing the Survival Analysis of Two or More Groups
525
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
525
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K